- Researchers have taken a truly innovative approach toward treating cancer in their attempt to use the body’s own immune system to fight off the disease. Thus far clinical trials for a cancer vaccine, called ImMucin, have produced promising results.
- According to Vaxil BioTherapeurtics, ImMucin's makers, the cancer vaccine triggers an immune response in about 90 percent of all types of cancer.
- The vaccine has performed consistently well in trials in patients with multiple myeloma and breast cancer, but it’s suspected that at this point Vaxil does not have the resources to further push the drug to the U.S. market.
Share This Article